Publication
Title
Telavancin
Author
Abstract
In September 2009, telavancin (Vibativ; Theravance/Astellas Pharma), a lipoglycopeptide antibiotic, was approved by the US FDA for the treatment of adult patients with complicated skin and skin structure infections.
Language
French
Source (journal)
Nature reviews drug discovery
Publication
2009
Volume/pages
8:12(2009), p. 929-930
Full text (Publishers DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 23.02.2011
Last edited 22.11.2016
To cite this reference